Enrichment Strategies for Systemic Sclerosis-Interstitial Lung Disease Trials.
作者信息
Volkmann Elizabeth R, Tashkin Donald P
机构信息
Department of Medicine David Geffen School of Medicine at UCLA Los Angeles, California.
出版信息
Am J Respir Crit Care Med. 2024 May 1;209(9):1067-1068. doi: 10.1164/rccm.202401-0246ED.
Abstract
摘要
相似文献
1
Enrichment Strategies for Systemic Sclerosis-Interstitial Lung Disease Trials.系统性硬化症-间质性肺病试验的富集策略
Am J Respir Crit Care Med. 2024 May 1;209(9):1067-1068. doi: 10.1164/rccm.202401-0246ED.
2
Treatment of systemic sclerosis.系统性硬化症的治疗
Rheum Dis Clin North Am. 1996 Nov;22(4):893-907. doi: 10.1016/s0889-857x(05)70307-0.
3
Summary for Clinicians: Clinical Practice Guideline for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations.临床医生摘要：系统性硬化症相关间质性肺疾病治疗临床实践指南：循证推荐
Ann Am Thorac Soc. 2024 Jan;21(1):12-16. doi: 10.1513/AnnalsATS.202309-760CME.
4
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.系统性硬化症临床试验中需考虑的间质性肺疾病要点。
Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203.
5
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.系统性硬皮病相关间质性肺病的治疗：现有和新兴疗法的综述。
Ann Am Thorac Soc. 2016 Nov;13(11):2045-2056. doi: 10.1513/AnnalsATS.201606-426FR.
6
Systemic sclerosis-associated interstitial lung disease.系统性硬皮病相关性间质性肺疾病。
Lancet Respir Med. 2020 Mar;8(3):304-320. doi: 10.1016/S2213-2600(19)30480-1. Epub 2020 Feb 27.
7
[New developments in systemic sclerosis-associated interstitial lung disease].系统性硬化症相关间质性肺疾病的新进展
Rev Med Suisse. 2020 Nov 18;16(715):2218-2223.
8
Systemic sclerosis related interstitial lung disease: What is the recommended treatment?系统性硬化症相关间质性肺疾病：推荐的治疗方法是什么？
Reumatol Clin (Engl Ed). 2021 Oct;17(8):490. doi: 10.1016/j.reumae.2019.12.005.
9
[Systemic sclerosis-related interstitial lung disease: Diagnostic and therapeutic strategy in the light of recent clinical trials].[系统性硬化症相关间质性肺疾病：基于近期临床试验的诊断与治疗策略]
Rev Med Interne. 2022 Jun;43(6):365-374. doi: 10.1016/j.revmed.2021.12.003. Epub 2022 Feb 15.
10
Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma.系统性硬化症治疗的新进展及其在儿童硬皮病中的适用性。
Rheum Dis Clin North Am. 2021 Nov;47(4):757-780. doi: 10.1016/j.rdc.2021.07.004. Epub 2021 Sep 2.
引用本文的文献
1
Pragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multiperspective Qualitative Study.类风湿关节炎相关间质性肺疾病的实用比较疗效试验：一项多视角定性研究。
CHEST Pulm. 2025 Jun;3(2). doi: 10.1016/j.chpulm.2025.100159. Epub 2025 Mar 24.
2
Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease.系统性硬化症相关间质性肺疾病的个性化医疗
Curr Treatm Opt Rheumatol. 2025 Dec;11(1). doi: 10.1007/s40674-024-00221-7. Epub 2025 Jan 9.
3
Understanding Late-Onset Interstitial Lung Disease in Systemic Sclerosis: Implications for Clinical Practice and Trial Design.系统性硬化症中迟发性间质性肺疾病的认识：对临床实践和试验设计的启示
Arthritis Rheumatol. 2025 Apr;77(4):380-382. doi: 10.1002/art.43053. Epub 2024 Dec 1.
本文引用的文献
1
Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy.结合临床和生物学数据预测系统性硬化症患者在接受免疫调节治疗后发生进行性肺纤维化的情况。
ACR Open Rheumatol. 2023 Oct;5(10):547-555. doi: 10.1002/acr2.11598. Epub 2023 Aug 17.
2
Rare-disease researchers pioneer a unique approach to clinical trials.罕见病研究人员开创了一种独特的临床试验方法。
Nat Med. 2023 Aug;29(8):1884-1886. doi: 10.1038/s41591-023-02333-4.
3
Designing clinical trials for rare diseases: unique challenges and opportunities.罕见病临床试验设计：独特的挑战与机遇
Nat Rev Methods Primers. 2022 Mar 10;2(1). doi: 10.1038/s43586-022-00100-2. eCollection 2022 Dec.
4
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.从欧洲硬皮病试验和研究中探讨系统性硬化症进行性间质性肺病的队列富集策略。
Chest. 2023 Mar;163(3):586-598. doi: 10.1016/j.chest.2022.09.044. Epub 2022 Oct 14.
5
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.特发性肺纤维化（更新版）和成人进展性肺纤维化：美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会临床实践指南。
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
6
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.托西珠单抗治疗系统性硬化症：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Respir Med. 2020 Oct;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. Epub 2020 Aug 28.
7
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.尼达尼布治疗系统性硬化症相关间质性肺疾病。
N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20.
8
Adaptive designs in clinical trials: why use them, and how to run and report them.临床试验中的适应性设计：为何使用它们，以及如何实施和报告它们。
BMC Med. 2018 Feb 28;16(1):29. doi: 10.1186/s12916-018-1017-7.
9
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.霉酚酸酯与口服环磷酰胺治疗硬皮病相关间质性肺病（SLS II）：一项随机对照、双盲、平行组试验。
Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.
10
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.托西珠单抗皮下注射治疗系统性硬化症成人患者的安全性和有效性（faSScinate）：一项 2 期、随机、对照试验。
Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5.
Zotero 插件